MedTrace Logo

A Study of LY3209590 in Participants With Type 1 Diabetes

NCT04450407 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 266

Last updated 2022-10-27

Study results available
· View outcomes & findings →

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

LY3209590

Administered SC

DRUG

Insulin Degludec

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-06
Primary Completion
2021-10-01
Completion
2021-10-01
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Germany
  • Puerto Rico
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450407 on ClinicalTrials.gov